Sector
PharmaceuticalsOpen
₹1,368Prev. Close
₹1,368.8Turnover(Lac.)
₹33,191.47Day's High
₹1,424.6Day's Low
₹1,363.852 Week's High
₹1,45752 Week's Low
₹641.05Book Value
₹97.21Face Value
₹2Mkt Cap (₹ Cr.)
76,331.86P/E
99.56EPS
13.76Divi. Yield
0.1515 May 2025
12:00 AM
AGM
Announcement Date: 15 May, 2025
9 Apr 2026
12:00 AM
Board Meeting
Agenda : Audited Result
30 Apr 2026
12:00 AM
Dividend
Dividend Amount: 1.2
Record Date: 08 May, 2026
Finished Dosage Formulations (FDF) business also saw a 27% growth, while the Generics business saw moderate growth of 5%
The said transaction falls under related party transactions. However, the same is being carried at arm’s length price.
| Y/e 31 Mar( In .Cr) | Mar-2026 | Mar-2025 | Mar-2024 | Mar-2023 |
|---|---|---|---|---|
Equity Capital | 107.97 | 107.85 | 107.79 | 107.73 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 5,143.97 | 4,456.1 | 4,099.26 | 3,949.09 |
Net Worth | 5,251.94 | 4,563.95 | 4,207.05 | 4,056.82 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Revenue | 4,707.04 | 4,768.72 | 2,797.33 | 2,026.84 |
yoy growth (%) | -1.29 | 70.47 | 38.01 | 7.13 |
Raw materials | -2,208.56 | -2,175.13 | -1,402.54 | -1,056.4 |
As % of sales | 46.92 | 45.61 | 50.13 | 52.12 |
Employee costs | -445.14 | -401.88 | -323.99 | -238.14 |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Profit before tax | 975.41 | 1,274.63 | 304.48 | 240.9 |
Depreciation | -235.48 | -196.64 | -183.85 | -121.23 |
Tax paid | -225.32 | -318.52 | -37.43 | -67.76 |
Working capital | 145.83 | 684.91 | 246.73 | 42.81 |
Other operating items |
| Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | -1.29 | 70.47 | 38.01 | 7.13 |
Op profit growth | -14.88 | 164.78 | 39.5 | -1.22 |
EBIT growth | -20.08 | 241.8 | 23.97 | -7.49 |
Net profit growth | -21.54 | 258.03 | 54.23 | -13.41 |
| Particulars (Rupees in Crores.) | Mar-2026 | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 |
|---|---|---|---|---|---|
Gross Sales | 6,812.9 | 5,553.96 | 5,040.83 | 6,040.55 | 4,935.57 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 6,812.9 | 5,553.96 | 5,040.83 | 6,040.55 | 4,935.57 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 54.95 | 75.1 | 26.34 | 6 | 15.3 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,838.3 | 146.85 | 4,40,793.82 | 608.7 | 0.87 | 4,887.27 | 93.23 |
Divis Laboratories Ltd DIVISLAB | 6,743 | 67.22 | 1,78,956.35 | 756 | 0.44 | 2,793 | 629.49 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 4,429.8 | 67.72 | 1,49,819.64 | 467 | 0.86 | 2,677 | 249.73 |
Cipla Ltd CIPLA | 1,351.8 | 31.77 | 1,09,370.14 | 384.64 | 0.96 | 3,840.92 | 423.36 |
Zydus Lifesciences Ltd ZYDUSLIFE | 1,070.8 | 29.18 | 1,07,757.6 | 1,722 | 0.09 | 3,564.6 | 235.25 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Independent Directo
Ravindranath Kancherla
Executive Director & CEO
CHAVA SATYANARAYANA
Executive Director & CFO
VENKATA RAVI KUMAR VANTARAM
Executive Director
Venkata Lakshmana Rao Chunduru
Executive Director
KRISHNA CHAITANYA CHAVA
Executive Director
Soumya Chava
Independent Non Exe. Director
Aruna Bhinge
Independent Non Exe. Director
Rajesh Koshy Chandy
Independent Non Exe. Director
Karnam Sekar
Independent Non Exe. Director
Ramesh Subrahmanian
Independent Director
Sutapa Banerjee
Independent Director
Shekhar Chintamani Mande
CS / Compliance Officer / Vice President - Legal
Venkateswar Reddy Gogireddy
Plot No 21 Jawaharlal Nehru,
Pharma City Parawada,
Andhra Pradesh - 531021
Tel: 91-891-3061222
Website: http://www.lauruslabs.com
Email: secretarial@lauruslabs.com; info@lauruslabs.com
Karvy Selenium Tow-B,
31&32 Financial Dist, Nanakramguda,
Hyderabad-500032
Tel: 91-40-67162222
Website: www.kfintech.com
Email: einward.ris@karvy.com
Summary
Laurus Labs Limited was originally incorporated as Laurus Labs Private Limited on September 19, 2005 at Hyderabad, Andhra Pradesh, India as a private limited company. The company was subsequently conv...
Read More
Reports by Laurus Labs Ltd
What is the Laurus Labs Ltd share price today?
What is the Market Cap of Laurus Labs Ltd?
What is the PE and PB ratio of Laurus Labs Ltd?
What is the 52 Week High and Low of Laurus Labs Ltd?
What is the CAGR of Laurus Labs Ltd?
What is the shareholding pattern of Laurus Labs Ltd?
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
